Kornimate/medical-research-clean huggingface dataset:
effectiveness of electro-press needle and gamma-oryzanol for menopause-associated hot flashes

Conditions: Hot Flashes; Acupuncture Therapy; Perimenopausal Disorder; Postmenopausal Symptoms

Summary: the investigators plan to conduct the randomized controlled trial to evaluate the effectiveness of electro-press needle (epn), a novel acupuncture needle combining shallow and gentle insertion with transdermal electrical stimulation, on menopause-associated hot flash in comparison with gamma-oryzanol group among women during menopausal transition and postmenopausal periods.

as the most common type of menopause-associated symptoms, hot flashes affect up to 85% of women aging between 40 and 65 years . in china, women suffer from hot flushes as long as 4 to 5 years on average, some of whom may bear the symptoms for 12 years.hormone replacement therapy (hrt) is generally recommended to relieve menopause-associated hot flashes.however, long-term usage of hrt may increase the incidence of endometrial, breast and ovarian cancer, thrombosis and strokes.results of previous studies indicated that acupuncture might help to relieve the symptoms.there is insufficient evidence supporting its effectiveness for relieving the hot flash symptom.

Eligibility criteria:
inclusion criteria: 1. aged between 40-60 years old; 2. scoring 14 points or more in at least one day during the one-week baseline assessment, or having an average of ≥ 7 moderate or severe heating per 24 hours recorded in hf dairy ; 3. fulfilling either condition mentioned below: 1. the last menstrual period was more than 12 months ago (including 12 months); 2. in the late menopausal transition, and has amenorrhea for more than 60 days; 3. fsh≥25iu, and has vasomotor symptoms of hf, sweating, insomnia, migraine, or restlessness, etc. 4. volunteer to participate in this study and sign the informed consent. exclusion criteria: 1. usage of hrt via transdermal administration in the previous one month, or via oral or intrauterine administration in the previous two months; usage of phytoestrogens therapy, transvaginal estrogen administration, or estrogen or progesterone injections in the previous three months; 2. bilateral salpingo-oophorectomy; 3. amenorrhea secondary to premature ovarian failure, ovarian cyst or tumor, thyroid disease, hyperprolactinemia, or cushing's syndrome, etc.; 4. accepted acupuncture or drugs to treat the symptoms of hf within the previous 3 months; 5. received radiotherapy or chemotherapy before; 6. coagulation dysfunction, or taking warfarin, heparin and other anticoagulant drugs at present; 7. suffering from skin diseases, such as eczema, psoriasis, etc.; 8. severe hepatic and renal insufficiency; 9. uncontrolled hypertension, diabetes or thyroid disease; 10. diabetic neuropathy and mental illness (including depression); 11. being pregnant, breastfeeding or planning to be pregnant during the trial; 12. regular usage of sedatives or anti-anxiety drugs; 13. smoking for more than 5 years (at least twenty cigarettes a day on average) , or with the problem of alcohol abuse; 14. installation of pacemakers; 15. poor compliance.

Keywords: gamma-oryzanol electro-press needle
emergent prep for iv dye in acute stroke patients with allergy

Conditions: Stroke; Dye Allergy

Summary: our institution implemented a protocol to administer an emergent iv dye preparation for stroke alert patients requiring advanced neuroimaging. the emergent iv dye preparation consists of diphenhydramine 50 mg iv once, famotidine 20 mg iv once, and dexamethasone 10 mg iv once, followed immediately by computed tomography (ct) angiography and/or ct perfusion.

patients with documented iv dye allergy were given emergent dye preparation immediately prior to advanced neuroimaging that consisted of three drugs: diphenydramine 50 mg iv, famotidine 20 mg iv, and dexamethasone 10 mg iv. in contrast, elective dye preparation commonly done in non-emergent or outpatient settings is separated into two different options. the first option is for a patient to take prednisone 50 mg three times prior to the study: one tablet by mouth 13 hours prior, one tablet by mouth seven hours prior, and the last tablet by mouth one hour prior to the study. the second option is for the patient to be prescribed dexamethasone 4 mg or 6 mg dispensed four times: two tablets by mouth 12 hours prior to the study and 2 tablets by mouth one hour prior to the study. if the patient is prescribed dexamethasone, they also take famotidine 150 mg and diphenhydramine 50 mg, both drugs by mouth 12 hours prior and one hour prior to the study. to evaluate the relationship between dye allergy and any adverse reactions, our study's inclusion criteria consisted of all stroke alert patients from 2021-2022 who required advanced neuroimaging of ctp/cta and received emergent iv dye preparation. exclusion criteria included patients who reported dye allergies specific to airway edema or anaphylaxis. a retrospective chart review was done to evaluate stroke patient's stated allergies, the number of patients that received emergent iv dye preparation, and any adverse reactions despite the emergent iv dye preparation. data was then analyzed to determine if there was a relationship between prior contrast dye allergy and allergic reactions that occurred after emergent iv dye administration.

Eligibility criteria:
inclusion criteria: stroke alert patients that required advanced neuroimaging of ctp/cta and received emergent iv dye preparation - exclusion criteria: patients who reported dye allergies specific to airway edema or anaphylaxis -

Keywords: stroke emergent iv dye prep dye allergy
the impact of daily carbohydrate intake on glycemic control in children and adolescents with type 1 diabetes using an advanced hybrid closed-loop system

Conditions: Diabetes Mellitus, Type 1

Summary: lifestyle factors, including diet, play an important role in the achievement of glycemic targets in patients with diabetes, even with the use of automated insulin delivery (aid) systems. advanced hybrid closed-loop systems (ahcl), by implementing innovative and powerful control algorithms, have been shown to improve the post-meal glycemic control in their users through the delivery of automatic correction boluses. however, data about the influence of the daily amount of carbohydrate intake on glycemic outcomes in youth with type 1 diabetes using ahcl are missing. therefore, this study will evaluate the association between daily carbohydrate intakes and meal patterns on glycemic control of young people living with type 1 diabetes using an ahcl system (medtronic minimed 780g; medtronic, northridge, california) under real-life conditions.


Eligibility criteria:
inclusion criteria: * patients with type 1 diabetes * patients aged 7-18 years * patients using medtronic minimed 780g with smartguard activated * patients whose informed consent has been obtained * \>70% cgm data during observational period exclusion criteria: * patients with partial clinical remission according to the hvidovre study group definition * concomitant treatment with steroids or other drugs known to interfere with blood glucose levels * previous diagnosis of psychological or eating disorders

Keywords: minimed 780g automated insulin delivery nutrition diet time in range insulin pump
development of peanut, sesame, and tree nut allergy in polish children at high risk of food allergy

Conditions: Atopic Dermatitis; Food Allergy; Peanut Allergy; Tree Nut Allergy

Summary: the aim of the study is to assess the prevalence of peanut, tree nuts, and sesame allergy in polish children at high risk of food allergy. additionally, the timing of the development of peanut, tree nuts and sesame allergy in the first three years of life in a high-risk population will be assessed.

introduction: peanut allergy (pa) has become a health concern world-wide for several decades. sesame allergy, although less prevalent, is also causing growing concern. peanut, tree nuts, and sesame allergy co-exist in 60% of children. although the majority of pa cases come from the general population, there are well-established risk factors for this allergy, such as eczema and egg allergy. in the learning early about peanut (leap) study, early introduction of peanut into the diet of children with moderate-to-severe eczema or egg allergy was proven to be effective in pa prevention. this strategy has now been adopted by national allergy societies in the usa and australia as part of the weaning guidance for the high-risk populations.however, it is not known whether early introduction of peanut is also justified in other populations where peanut consumption has traditionally been lower. getting insight into the prevalence of nut and sesame allergy in the cohort of infants and toddlers in central europe is needed to guide early dietary intervention strategies. methods: 240 children with eczema or egg allergy will undertake extensive assessment of peanut, tree nuts (hazelnut, almond, cashew, pistachio, walnut, macadamia) and sesame allergy status through consumption history, skin testing, specific immunoglobulin e measurement (sige) and oral food challenges (ofcs).

Eligibility criteria:
inclusion criteria: * moderate or severe eczema and/or egg allergy, * at least one complementary food already introduced, * signed informed consent. assessment of eczema severity: eczema severity will be assessed based on the objective scoring atopic dermatitis (scorad), use of topical steroids, calcineurin inhibitors or systemic treatment as well as history of hospital admission. definition of egg allergy: participants with a documented ige-mediated egg allergy will be identified by a convincing history of a reaction in the presence of a positive skin prick test (spt) (wheal diameter of 3 mm or greater with egg white extract) or an spt ≥ 5mm with no history of a reaction. exclusion criteria: * inability to withdraw antihistamines for at least 5 days prior to testing, * use of prohibited medication such as beta-blockers, angiotensin-converting-enzyme inhibitors (ace-i) and biological treatments affecting the immunological response, * uncontrolled asthma or eczema which does not warrant readiness for a food challenge within the study time frame, * chronic urticaria, * chronic systemic diseases.

Keywords: atopic dermatitis peanuts tree nuts sesame food allergy children
registry for mayo clinic adult congenital heart disease control population

Conditions: Healthy

Summary: this research study is being done to provide comparative data to the mayo clinic adult congenital heart disease registry.


Eligibility criteria:
inclusion criteria: * bmi ≤ 30. * no current cardiac medications. * systolic bp ≤ 140 mmhg. * diastolic bp ≤ 90 mmhg. * capacity to consent. exclusion criteria: * to be assessed via emr screening. * patient confirmation during screening visit. * screening tests as applicable. * history of cardiovascular disease. egfr \< 30. * current orthopedic limitations.
study of chiropractic and neuromuscular reeducation as a treatment for autism symptoms

Conditions: Autism

Summary: this study explores the effectiveness of chiropractic and neuromuscular reeducation as complementary and alternative medicine treatment approaches for autism. our investigation maintains the following three hypotheses: 1. spinal manipulative therapy (smt) will reduce the presentation of autistic symptoms in children. 2. spinal manipulative therapy (smt) in conjunction with neuromuscular reeducation will reduce the presentation of autistic symptoms in children. 3. the presentation of autistic symptoms in children will significantly differ between the treatment groups of spinal manipulative therapy and spinal manipulative therapy in unification with neuromuscular reeducation.

we aim to describe and illustrate the roles of spinal manipulative therapy and neuromuscular reeducation in autistic children at a cam university health center with regard to the following: 1. to measure the safety and efficacy of spinal manipulative therapy for the autism spectrum disorders 2. to measure the safety and efficacy of spinal manipulative therapy and neuromuscular reeducation for the treatment of the autism spectrum disorders 3. to begin to establish or debunk debated smt treatment for autism 4. to evaluate, gauge, and improve current autism assessment tools by exploring face validity of the measures as indicated by ongoing data collection

Eligibility criteria:
inclusion criteria: * children diagnosed by a physician with an autism spectrum disorder between the ages of 5 and 15 * children with parents able to bring their child to the university health center two times a week for 12 weeks * children assessed to have a level of functioning that is conducive to experiencing and undergoing chiropractic treatment at the university health center. * children without the presentation and diagnosis of comorbidity exclusion criteria: * children with comorbidity or multiple diagnoses (mental retardation, chromosomal disorders) * children undergoing another treatment for their disorder, other than a form of behavioral therapy (aba or dtt) by a trained or licensed mental health professional. * children taking medication that is not deemed to be stabilized by a primary care physician, including medication dosages that is likely to be shifted and changed during the 12 weeks of treatment in this investigation. * children assessed to have severe behavioral impediments not conducive to chiropractic treatment at the university health center.
99mtc-hpark2 spect/ct for the detection of her2-positive breast cancer

Conditions: Breast Cancer

Summary: this is an open-label single photon emission tomography/computed tomography (spect/ct) study to investigate the diagnostic performance and evaluation efficacy of 99mtc-hpark2 in breast cancer patients. a single dose of 11.1mega-becquerel (mbq) per kilogram body weight 99mtc-hpark2 will be injected intravenously. visual and semiquantitative method will be used to assess the spect/ct images.

99mtc-hpark2 is an affibody probe targeting her2. the investigators will determine the use of 99mtc-hpark2 spect/ct in the detection of her2-positive breast cancer, and to compare its diagnostic value with routine immunohistochemistry (ihc) pathological staining. her2 imaging, specifically to her2 receptor expressed on malignant breast cancer cell surface, might help for targeted therapy with monoclonal antibody such as trastuzumab in breast cancer, and may improve the treatment strategy of breast cancer. the investigator will determine the use of 99mtc-hpark2 spect/ct in stratifying breast cancer.

Eligibility criteria:
inclusion criteria: * patients in suspicion of breast cancer by mammography or ultrasonography,and being able to provide basic information and sign the written informed consent form exclusion criteria: * the exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study, and undergoing any preceding local or systemic therapies that might interfere with her2 binding.

Keywords: spect/ct her2 imaging
the effects of frailty on opioid consumption

Conditions: Frailty; Opioid Use; Knee Arthropathy

Summary: the frail scale will be applied to patients at the preoperative visit. according to the frail scale, patients will be divided into 3 groups as non-frail (group i), pre-frail (group ii) and frail (group iii). after routine preoperative preparation and monitoring, patients will be given spinal anesthesia. demographic data and intraoperative data of the patients will be recorded. patients will be transferred to the post-operational post-operative care unit (pacu) and patient-controlled analgesia (pca) will be applied to each patient with a standard protocol. in the postoperative period, the need for analgesics will be recorded for 24 hours, and if additional analgesics are needed, they will be recorded. pain scores of the patients will be evaluated for 24 hours.


Eligibility criteria:
inclusion criteria: * patients who will undergo unilateral, primary total knee arthroplasty * patients who will be operated with spinal anesthesia exclusion criteria: * patients with asa iv and above physical status * uncooperative patients * patients who do not speak turkish * patients on routine opioid use
primary care-based follow-up of cancer survivors of the prostate and kidney

Conditions: Prostate Cancer; Kidney Cancer

Summary: in france, the second cancer plan of 2009-2013 aimed to strengthen the role of mt by putting it back at the center of patient monitoring, in particular by asking "regional health agencies to encourage and support local experiments" which aim for better coordination between the city and the hospital. the third cancer plan for 2014-2019 insists on this measure because it had proven to be unproductive, and recommends, in addition to the creation of a nurse dedicated to the coordination of care between community medicine and the hospital, the creation of a direct telephone line to reach the hospital medical team. this measure is mainly aimed at the follow-up of certain cancers that do not require the technical support of the hospital, as is the case in the post-operative follow-up of rcc and cap, where the additional examinations carried out during follow-up are carried out in the city. the research hypothesis is that this new method of monitoring had a positive impact on care in terms of quality, accessibility, organization and costs.


Eligibility criteria:
inclusion criteria: * adult subjects (≥18 years old) * patient operated on for localized prostate or kidney cancer * patient followed at the hus during the period from 01/01/2015 to 12/31/2021 * subject who has not expressed his opposition, after information, to the reuse of his data for the purposes of this research. exclusion criteria: * subject having expressed opposition to participating in the study * patient under active therapy (hormonotherapy, systemic treatment) for the pathology studied * impossibility of providing the subject with informed information (difficulties in understanding the subject, etc.) * subject under judicial protection * subjects under guardianship or curatorship

Keywords: prostate cancer kidney cancer
comparison of two high performance guidewires in ercp

Conditions: Stenosis of Bile Duct

Summary: in ercp guidewires are used for the insertion of endoprostheses and the cannulation of stenosis. this leads to two essential requirements for the wire systems: the use of a (highly) flexible, hydrophilic wire to achieve successful and rapid passage of the narrow passage; for additional intervention, modern wires are equipped with a stable shaft with which e.g. bougies, dilatation catheters, or stents can be introduced. guidewires are available with angled or straight tips whose use differ regionally. guidewires with angled tips are used predominantly in japan, whereas in the western world incl. germany straight wires are commonly used. in a recently published study examining the intubation of the native papilla, successful intubation of the papilla was faster with guidewires with angled tips than with guidewires with straight tips. however, this did not result in an effect upon the time-independent rate of the successful papilla intubation. the investigators test the hypothesis that 1) a higher success rate of the ercp can be achieved with the use of an angled guidewire than with a straight guidewire and 2) a higher success rate of the ercp can be achieved with the use of a type 1 guidewire than with a type 2 guidewire

this is a randomized, multicentric study.

Eligibility criteria:
inclusion criteria: * obstruction of the biliary tract (cross sectional imaging or ultrasonography/lab data exclusion criteria: * operatively alternated anatomy of the patient

Keywords: stenosis bile duct guidewire ercp
immunolocalization of 1,25,dihydroxyvitamin d3 in aggressive periodontitis patients

Conditions: Aggressive Periodontitis

Summary: the study was to intended to visualize the nuclear localization of vitamin d receptor in oral tissues of aggressive periodontitis patients to better understand the potential for receptor in disease activity or progression.

aggressive periodontitis (agp) is an infectious disease of the periodontium which affects young adults, causing damage to the supporting apparatus of the teeth, leading to rapid bone resorption and tooth loss. its clinical features have been shown to result from several genetic and environmental factors. this has increased the interest to research those genetic host factors as they may provide useful risk markers, reveal important information regarding the pathogenesis and also identification of effective preventive agents that might help decrease the disease burden. 1,25-dihydroxyvitamin d3,apart from these traditional calcium-related actions, this active form is being increasingly recognized for its potent anti-proliferative, anti-differentiative and immunomodulatory activities. the calcitriol activity is largely mediated by the vitamin d receptor (vdr) whose expression has been described in some tissues. vdr is localized in both the cytosol and nucleus and accumulates in the nucleus in response to 1,25,dihydroxyvitamin d3 binding. expression and nuclear activation of the vdr are necessary for the effects of vitamin d. thus, alterations in the vitamin d pathway lead to disturbances in mineral metabolism. it may be hypothesized that the rapid bone loss which occurs in aggressive periodontitis patients may be due to decreased or absence of expression of vitamin d receptor in the nucleus.

Eligibility criteria:
inclusion criteria: 1. generalized aggressive periodontitis patients were onset of periodontal disease at \ 6mm and radiographic evidence of alveolar bone loss, three of which were not first molar or incisor under test group. 2. control group includes systemically and periodontally healthy individuals who is of same age as that of test group. - exclusion criteria 1. subjects taking drugs for vitamin d or calcium 2. subjects received periodontal therapy within previous year 3. pregnant subjects 4. smokers 5. patients with systemic diseases -
efficacy of extra virgin olive oil (evoo) supplementation on hand-foot syndrome incidence in patients with capecitabine

Conditions: Hand and Foot Skin Reaction; Hand and Foot Syndrome; Capecitabine

Summary: the study was aimed to evaluate the efficacy of extra virgin olive oil (evoo) supplementation compared to placebo to prevent hfs by observing changes in serum cox 2, malondialdehyde (mda), and tnf α levels in breast cancer and colorectal cancer patients undergoing capecitabine chemotherapy. current study was designed as a single-center prospective randomized clinical trial. the patients were stage iii or stage iv colorectal and breast cancer patients receiving capecitabine-based chemotherapy who enrolled in the trial voluntarily. all patients were divided randomly into three groups treated with evoo, olive oil, or placebo. the incidence of hand foot syndrome was documented. the serum cox 2, malondialdehyde (mda), and tnf α levels before and after chemotherapy was documented.


Eligibility criteria:
inclusion criteria: * patients pathologically and clinically diagnosed with iii or iv stadium of breast cancer or colorectal cancer. * fully recovered after curative resection within 8 weeks * receive adjuvant capecitabine based chemotherapy exclusion criteria: * did not meet the eligibility criteria for chemotherapy * had previous allergy with capecitabine or olive oil